Cost-Effectiveness of brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma

References

• Hess G, Dreyling M, Oberic L, et al. A comparison of overall survival with brexucabtagene autoleucel (brexu-cel) CAR T-cell therapy (ZUMA-2) and standard of care (SCHOLAR-2) in patients with relapsed/refractory mantle cell lymphoma (/R MCL) previously treated with a covalent bruton tyrosine kinase inhibitor (BTKi). Blood. 2022;140(Supplement 1):10296–10299. (
   Google Scholar
• Eyre TA, Walter HS, Iyengar S, et al. Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after bruton kinase inhibitor therapy. Haematologica. 2019;104(2):e68–e71.
   PubMed Web of Science ®Google Scholar
• McCulloch R, Visco C, Eyre TA, et al. Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy. Br J Haematol. 2020;189(4):684–688.
   PubMed Web of Science ®Google Scholar
• Martin P, Maddocks K, Leonard JP, et al. Postibrutinib outcomes in patients with mantle cell lymphoma. Blood. 2016;127(12):1559–1563.
   PubMed Web of Science ®Google Scholar
• Jain P, Kanagal-Shamanna R, Zhang S, et al. Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. Br J Haematol. 2018;183(4):578–587.
   PubMed Web of Science ®Google Scholar
• Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):1331–1342.
   PubMed Web of Science ®Google Scholar
• Wang M, Munoz J, Goy A, et al. Three-year follow-up of KTE-X19 in patients with mantle cell lymphoma, including high-risk groups, in the ZUMA-2 study. J Clin Oncol. 2023;41(3):555–567.
   PubMed Web of Science ®Google Scholar
• Munshi PN, Hamadani M, Kumar A, et al. ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma. Bone Marrow Transplant. 2021;56(12):2911–2921.
   PubMed Web of Science ®Google Scholar
• AIFA Classificazione, ai sensi dell’art. 12, comma 5, della legge 8 novembre 2012, n. 189, del medicinale per uso umano «tecartus», approvato con procedura centralizzata. (determina n. 47/2021). (21A02163). Gazzetta Ufficiale n. 12th April 2021;87:27-29, https://www.gazzettaufficiale.it/eli/id/2021/04/12/21A02163/sg.
   Google Scholar
• AIRTUM The burden of rare cancers in Italy. Italian cancer figures. Report. Epidemiologia & Prevenzione. 2015;2016(Suppl1):1–127.
   Google Scholar
• Felizzi F, Paracha N, Pöhlmann J, et al. Mixture cure models in oncology: a tutorial and practical guidance. Pharmacoecon Open. 2021;5(2):143–155.
   PubMed Web of Science ®Google Scholar
• Bansal A, Sullivan SD, Lin VW, et al. Estimating long-term survival for patients with relapsed or refractory large B-cell lymphoma treated with chimeric antigen receptor therapy: a comparison of standard and mixture cure models. Med Decis Making. 2019;39(3):294–298.
   PubMed Web of Science ®Google Scholar
• Wang M, Munoz J, Goy A, et al. Outcomes with KTE-X19 in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) in ZUMA-2 who had progression of disease within 24 months of diagnosis (POD24). J Clin Oncol. 2021;39(15_suppl):7547–7547.
   Web of Science ®Google Scholar
• Howlader N, Mariotto AB, Besson C, et al. Cancer-specific mortality, cure fraction, and noncancer causes of death among diffuse large B-cell lymphoma patients in the immunochemotherapy era. Cancer. 2017;123(17):3326–3334.
   PubMed Web of Science ®Google Scholar
• Dal Maso L, Panato C, Tavilla A, et al. Cancer cure for 32 cancer types: results from the EUROCARE-5 study. Int J Epidemiol. 2020;49(5):1517–1525.
   PubMed Web of Science ®Google Scholar
• Maurer MJ, Ghesquières H, Jais J-P, et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol. 2014;32(10):1066–1073.
   PubMed Web of Science ®Google Scholar
• Robinson SP, Boumendil A, Finel H, et al. Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT lymphoma working party. Bone Marrow Transplant. 2018;53(5):617–624.
   PubMed Web of Science ®Google Scholar
• Maziarz RT, Hao Y, Guerin A, et al. Economic burden following allogeneic hematopoietic stem cell transplant in patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2018;59(5):1133–1142.
   PubMed Web of Science ®Google Scholar
• Tan SS, Bakker J, Hoogendoorn ME, et al. Direct cost analysis of intensive care unit stay in four European countries: applying a standardized costing methodology. Value Health. 2012;15(1):81–86.
   PubMed Web of Science ®Google Scholar
• Campone M, Yang H, Faust E, et al. Cost of adverse events during treatment with everolimus plus exemestane or single-agent chemotherapy in patients with advanced breast cancer in Western Europe. J Med Econ. 2014;17(12):837–845.
   PubMedGoogle Scholar
• Wehler E, Zhao Z, Pinar Bilir S, et al. Economic burden of toxicities associated with treating metastatic melanoma in eight countries. Eur J Health Econ. 2017;18(1):49–58.
   PubMed Web of Science ®Google Scholar
• Howell T, Matza L, Jun MP, et al. PCN90. Assessment of utilities for adverse events (AES) associated with chimeric antigen receptor (CAR) T-cell therapy in large B-cell lymphoma (LBCL). Value Health. 2020;23(suppl 1):S39.
   PubMedGoogle Scholar
• Kurosawa S, Yamaguchi T, Mori A, et al. Prognostic impact of pre-transplantation quality of life and its post-transplantation longitudinal change after allogeneic hematopoietic cell transplantation: a prospective study that administered the short-form health survey (SF-12) and EuroQol 5. Transplant Cell Ther. 2021;27(11):935.e1-935–e9.
   Google Scholar
• Simons CL, Malone D, Wang M, et al. Cost-effectiveness for KTE-X19 CAR T therapy for adult patients with relapsed/refractory mantle cell lymphoma in the United States. J Med Econ. 2021;24(1):421–431.
   PubMed Web of Science ®Google Scholar
• Martone N, Lucioni C, Mazzi S, et al. Valutazione di costo-efficacia dei nuovi farmaci oncologici immessi sul mercato italiano. Global Reg Health Techn Assess. 2014;1(2):31–43.
   Google Scholar
• Report tecnico Yescarta. 2021. (28th July). AIFA web site https://www.aifa.gov.it/documents/20142/1307543/ Yescarta_Report_Tecnico_28.07.2021.pdf.
   Google Scholar
• Marchetti M, Martelli E, Zinzani PL. Cost-effectiveness of axicabtagene ciloleucel for relapsed or refractory dffuse large B-cell lymphoma in Italy. Blood. 2018;132(Supplement 1):4779–4779.
   Google Scholar
• Report tecnico Kymriah. 2021. (20th Sepetmber). AIFA web site https://www.aifa.gov.it/documents/20142/1307543/Kymriah_Report_Tecnico_20.09.2021.pdf.
   Google Scholar
• Maglinte GA, Simons CL, Wang M, et al. Cost-effectiveness of KTE-X19 car T therapy following bruton tyrosine kinase inhibitor treatment for relapsed/refractory mantle cell lymphoma in England. Bone Marrow Transplantation. 2021;56:195–196.
   PubMed Web of Science ®Google Scholar
• Marchetti M. Cost-effectiveness of kinase inhibitors for hematologic malignancies: a systematic and critical review. Expert Rev Pharmacoecon Outcomes Res. 2017;17(5):469–480.
   PubMed Web of Science ®Google Scholar
• Marchetti M, Gale RP, Barosi G. Cost-effectiveness of post-autotransplant lenalidomide in persons with multiple myeloma. Medit J Hematol Infect Dis. 2021;13(1):e2021034.
   PubMedGoogle Scholar
• Marchetti M, Cuneo A, Mauro FR, et al. Is idelalisib cost-effective for refractory/relapsed chronic lymphocytic leukemia? A decision analysis in the second-line setting. Blood. 2015;126(23):3305–3305.
   Web of Science ®Google Scholar
• Marchetti M, Barosi G. Should I transplant this patient with paroxysmal nocturnal hemoglobinuria? A cost-effectiveness analysis of eculizumab versus allogeneic stem cell transplant. Blood. 2014;124(21):735–735.
   Web of Science ®Google Scholar
• Wang M, Munoz J, Goy A, et al. Three-year follow-up of KTE-X19 in patients with relapesd-refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study. J CLin Oncol 2022;40 (16_suppl):7518 Subsequently fully published: DOI: 10.1200/JCO.22.01797 Journal of Clinical Oncology 41, no. 14 (May 10, 2023) 2594-2606.
   Google Scholar
• Banerjee R, Midha S, Kelkar AH, et al. Synthetic control arms in studies of multiple myeloma and diffuse large B-cell lymphoma. Br J Haematol. 2022;196(5):1274–1277.
   PubMed Web of Science ®Google Scholar
• CONFERENZA DELLE REGIONI E DELLE PROVINCE AUTONOME 15/61/CR05/C7 Accordo per la compensazione della mobilità sanitaria interregionale anno 2014.
   Google Scholar
• Visco C, Chiappella A, Nassi L, et al. Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from fondazione italiana linfomi. Lancet Haematol. 2017;4(1):e15–2e0.
   PubMed Web of Science ®Google Scholar
• Cartoni C, Brunetti GA, D'Elia GM, et al. Cost analysis of a domiciliary program of supportive and palliative care for patients with hematologic malignancies. Haematologica. 2007;92(5):666–673.
   PubMed Web of Science ®Google Scholar